Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated to proteinaceous toxin or fragment thereof
Reexamination Certificate
2007-10-30
2007-10-30
Wehbé, Anne Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated to proteinaceous toxin or fragment thereof
C424S178100, C424S093700, C530S387100, C530S387300, C530S388700, C530S391700
Reexamination Certificate
active
09568834
ABSTRACT:
The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.
REFERENCES:
patent: 5239062 (1993-08-01), Blattler et al.
patent: WO93/04187 (1993-03-01), None
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8: 53-69.
Miller et al.; Targeted v ectors for gene therapy, 1995, FASEB J 9: 190-199.
Reiter et. al., Peptide-specific killing of antigen-presenting cells by a with T cell receptor-like specificity, 1997. Proc Natl Acad. Sci., vol. 94: 4631-4636.
Deonarain. Ligand-targeted receptor-mediated vectors for gene delivery. 1998. Exp. Opin. Ther. Patents. 8, 53-69.
Miller et al. Targeted vectors for gene therapy. 1995. FASEB J. 9, 190-199.
Francisco et al. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. 1997. Blood, 89 (12), 4493-4500.
Hu et al. Depletion of T lymphocytes with immunotoxin retards the progress of experimenatal allergic encephalomyelitis in rhesus monkeys. 1997. Cellular Immunology. 177, 26-34.
Sekine, et al., Oct. 1997, Role of Passenger Leukocytes in Allograft Rejection, J. Immunol., vol. 159, pp. 4084-4093.
Arnold, et al., 1995, J. Exp. Med., 182:885-889.
Arnold, et al., 1997, J. Exp. Med. 186:461-466.
Banchereau, et al., 1998, Nature 392:245-252.
Basclga, et al., 1998, Cancer Res., 58:2825-2831.
Bera, et al., 1998 Molecular Medicine, 4:384-391.
Bevan, 1976, J. Exp. Med., 143:1283-1 288.
Bevan, 1995, J. Exp. Med. 182:639-641.
Bird, et al., 1988, Science, 242:423-426.
Bix, et al., 1991, Nature, 349:329-331.
Bolognesi, et al., 1998 Brit. J. Haematoli, 101:179-188.
Bonini, et al., 1997, Science, 276:1719-1 724.
Bordignon, et al., 1995, Human Gene Therapy, 6:813-819.
Braun, et al., 1990, Biology of Reproduction, 43:684-693.
Burbage, et al., 1997, Leukemia Res., 21:681-690.
Burton, et al., 1994, Adv. Immunol., 57:191-280.
Carbone, et al., 1989, Cold Spring Harbor Symp. Quant. Biol., 1:551-555.
Carbone, et al., 1990, J. Exp. Med., 171:377-387.
Champlin, 1993, Leukemia and Lymphoma, 11:149-152.
Chandler, et al., 1996, Seminars in Pediatric Surgery, 5:206-211.
Collins, et al., 1994, Blood, 84:333a.
Collinson, et al., 1994, J. Immunopharmacology, 16:37-49 (p. 42 intentionally omitted).
Conry, et al., 1995, J. Immunotherapy, 18:231-241.
Essand, et al., 1998, Internatl. J. Cancer, 77:123-127.
Faguet, et al., 1997, Leukemia & Lymphoma, 25:509-520.
Ferrara, 1993, Curr. Opinion in Immunol., 5:794-799.
Ferrara, et al., 1993, Transplantation Proceedings, 25:1216-1217.
Ferrara, et al., 1994, Bone Marrow Transplantation, 14:183-184.
Flavell, et al., 1995, Brit. J. Cancer, 72:1373-1379.
Francisco, et al., 1998, Leukemia and Lymphoma, 30:237-245.
Frankel, et al., 1997, Leukemia & Lymphoma, 26:287-298.
Gaziev, et al., 1997, Transplantation, 63:854-860.
Germain, 1994, Cell, 76:287-299.
Ghetie, et al., 1997, Mol. Med. 3:420-427.
Gu, et al., 1997, Thrombosis and Hematocyst, 77:755-759.
Horowitz, et al., 1990, Blood 75:555-562.
Huston et al., 1988, Proc. Natl. Acad. Sci. USA, 85:5879-5883.
Huang et al., 1996, Immunity, 4:349-355.
Huang, et al., 1994, Science, 264:961-965.
Koller, et al., 1990, Science 248:1227-1230.
Knowles, et al., 1987, Anal. Biochem., 160:440-443.
Kolb, et al., 1995, Blood, 86:2041-2050.
Korngold, et al., 1982, J. Exp. Med. 155:872-883.
Korngold, et al., 1983, Immunol. Rev., 71:5-29.
Korngold, et al., 1987, Transplantation, 44:335-339.
Korngold, et al., 1987, J. Exp. Med., 165:1552-1564.
Kreitman, et al., 1997, Blood, 90:252-259.
Kreitman, et al., 1998, Advanced Drug Delivery Reviews, 31:53-88.
Kurts, et al., 1998, J. Exp. Med., 188:409-414.
Kuzel, et al., 1993, Leukemia & Lymphoma, 11:369-377.
Lammert, et al., 1997, Eur. J. Immunol., 27:923-927.
LeMaistre, et al., 1993, Cancer Res., 53:3930-3934.
Levy, et al., 1991, J. Clin. Oncol., 9:537-538.
Lucarelli, et al., 1997, Cancer Treatment and Research, 77:305-315.
Lynch, et al., 1997, J. Clin. Oncol., 15:723-734.
Mackall, et al., 1993, Blood, 82:2585-2594.
Mackall, et al., 1997, Blood, 89:3700-3707.
Mackall, et al., 1997, Immunol. Today, 18:245-251.
Mansfield, et al., 1997, Blood, 90:2020-2026.
Maraskovsky, et al., 1996, J. Exp. Med., 184:1953-1962.
Marks, et al., 1991, J. Mol. Biol., 222:581-597.
Matzinger, 1977, Cell. Immunol. 33:92-100.
Maurer-Gebhard, et al., 1998, Cancer Res., 58:2661-2666.
Metlay, et al., 1990, J. Exp. Med., 171:1753-1771.
Minasi, et al., 1993, J. Exp. Med., 177:1451-1459.
Moreland, et al., 1995, Arthritis & Rheumatism, 38:1177-1186.
Nielsen, et al., 1991, Science, 254:1497-1500.
O'Marcaigh, et al., 1997, Curr. Opinion in Oncol. 9:126-130.
O'Toole, et al., 1998, Curr. Topics In Microbiol. & Immunol. 234:35-56.
Press, et al., 1998, Cancer Journal from Scientific American, 4:S19-S26.
Przepiorka, et al., 1995, Bone Marrow Transplantation, 16:737-741
Rowe, et al., 1994, Anal. Int. Med. 120:143-158.
Schnell, et al., 1996, Internatl. J. Cancer, 66:526-531.
sprent, et al., 1998, J. Exp. Med., 167:556-569.
Spyridonidis, et al., 1998, Blood, 91:1820-1827.
Srivastava et al., 1994, Immunogenetics, 39:93-98
Sullivan, et al., 1986, Blood, 67:1172-1175.
Sullivan, et al., 1989, New Engl. J. Med., 320:828-834
Truitt, et al., 1991, Blood, 77:2515-2523.
Tuszynski, et al., 1988, Blood, 72:109-115.
Udono, et al., 1993, J. Exp. Med., 178:1391-1396.
Winkler, et al., 1997, Annals of Oncol., 8:139-146.
Wright, et al., 1992, Critical Rev, in Immunol., 12:125-168.
Wu, 1997, Brit J. Cancer, 75:1347-1355.
Zdanovsky, et al., 1997, Faseb Journal, 11:A1325-A1325.
Anderson et al. (2005) “Distinct roles for donor-and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ” Blood 105: 2227-2234.
Bertolini et al. (1997) “A new “two step” procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation” Bone Marrow Transplant 19: 615-619.
Clark et al. (1994) “Antigen-specific deletion of cloned T cells using peptide-toxin conjugate complexed with purified class II major histocompatibility complex antigen” J. Biol. Chem. 269: 94-99.
Francisco et al. (1997) “Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1” J. Biol. Chem. 272(39): 24165-24169.
Freeman et al. (1997) “Immune system in suicide-gene therapy” The Lancet 349: 2-3.
Kreitman et al. (1998) “Immunotoxins for targeted cancer therapy” Adv. Drug Deliv. Rev. 31:53-88.
Matte et al. (2004) “Donor APCs are required for maximal GVHD but not for GVL” Nature Medicine 10: 987-992.
Mullen et al. (1994) “Metabolic suicide genes in gene therapy” Pharmacol. Ther. 63(2): 199-207.
Reff et al. “Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20” Blood 83(2): 435-445.
Rooijen et al. (1992) “Efficacy of various water-soluble chelator molecules in the liposome-mediated macrophage“suicide” technique” Journal of Pharmacological and Toxicological Methods, 28: 217-221.
Schultz et al. (1995) “Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease” Bone Marrow Transplant 16: 289-295.
Shlomchik et al. (1997) “Radioresistant host antigen presenting cells are required for acute graft-versus host disease induction” Blood 90:396a.
Wong et al. (1984) “Depletion of macrophages from heterogeneous cell populations by the use of carbonyl iron” Methods in Enzymology 108: 307-313.
Slaper-Cortenbach, et al, “Effective Purging of Bone Marrow by a Combination of Immunorosette Depletion and Complement Lysis” Experimental Hematology, 18, N
Emerson Stephen G.
Shlomchik Mark Jay
Shlomchik Warren D.
Cooley & Godward LLP
Wehbe Anne Marie
Yale University
LandOfFree
Prevention of immunoreactivity by depleting or inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of immunoreactivity by depleting or inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of immunoreactivity by depleting or inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857013